GHRH analog comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-02-14. Numbers and descriptions here follow the published literature rather than marketing material.
A documented effect of tesamorelin is a reduction in visceral adipose tissue in some study populations. Researchers have reported decreases in trunk fat measured by computed tomography alongside changes in lipid markers. The mechanism is thought to involve growth hormone-mediated lipolysis, though the precise contribution of direct versus indirect pathways is not fully resolved. Studies have generally examined defined groups over finite periods, so long-term outcomes are less well characterized. Findings have not been uniform across all trials.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). Its sequence corresponds to the 44-amino-acid form of human GHRH with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification slows enzymatic cleavage and extends the peptide's activity relative to the native hormone. The compound is produced by solid-phase peptide synthesis and supplied as a lyophilized powder. Researchers classify it as a GHRH receptor agonist. Its structure places it in the same family as other growth hormone secretagogues that act on the pituitary.
Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.
作用位置在垂体前叶。tesamorelin 与 GHRH 受体结合后激活腺苷酸环化酶，升高细胞内 cAMP，再经蛋白激酶 A 通路促进生长激素的合成与释放。由于它作用于内源调控节点，生长激素仍以脉冲方式分泌，而不是被持续抬升到固定水平。生长激素随后在肝脏等组织诱导胰岛素样生长因子 1 产生，构成完整的生长激素轴响应。
研究背景集中在特定人群的体成分改变，尤其是与脂肪分布异常相关的内脏脂肪堆积。不同地区对它的监管状态与获批适应症并不一致，部分市场仅限特定诊断人群使用。在一般人群中的长期效应、与其他激素的相互作用以及停药后的维持情况仍属开放问题，现有数据不足以给出普遍结论。
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | GHRH receptor agonist |
| Residue count | 44 amino acids | N-terminal trans-3-hexenoyl group |
| Approximate mass | About 5.1 kDa | Derived from the peptide sequence |
| Primary target | Pituitary GHRH receptor | Somatotroph cells of the anterior pituitary |
| Downstream marker | IGF-1 | Measured indirectly in circulation |
Physicochemical behavior is dominated by the peptide backbone. The molecule is hydrophilic and carries a net positive charge near neutral pH, owing to several arginine and lysine residues. In solution it adopts a largely unstructured conformation, and aggregation is a known concern for peptide products of this size. Oxidation of methionine and deamidation of asparagine or glutamine residues are the principal chemical degradation routes. These liabilities shape how the material is formulated, handled, and analyzed, and they explain why lyophilized presentations are common in research settings.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, built from 44 amino acids. Its sequence follows the natural human GHRH(1-44) backbone, with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification blocks recognition by dipeptidyl peptidase IV, the enzyme that rapidly truncates the native hormone in circulation. The result is a molecule with a substantially longer plasma residence time than unmodified GHRH, which makes it practical for clinical and laboratory study.
Clinical study of tesamorelin has centered on adults with HIV-associated lipodystrophy, a condition in which abdominal fat accumulates while peripheral fat is lost. In controlled trials, treated participants showed reductions in visceral adipose tissue measured by imaging, alongside modest shifts in some lipid values. Effects on subcutaneous fat were smaller and less consistent across studies. Whether these changes translate into fewer cardiovascular events remains an open question, because the trials were not designed or powered to answer it.
Tesamorelin is a synthetic peptide that acts as an analog of growth hormone-releasing hormone, a natural hypothalamic signal. Its sequence corresponds to the forty-four amino acid form of the human hormone, with a small acyl group attached near the amino terminus. That modification slows enzymatic breakdown and extends the time the peptide remains active in circulation. The compound was developed as a pharmacological way to raise endogenous growth hormone output rather than supplying the hormone directly.
=== Treatment of deficiency === Severe vitamin B12 deficiency is initially corrected with daily intramuscular injections of 1000 μg of the vitamin, followed by maintenance via monthly injections of the same amount or daily oral dosing of 1000 μg. The oral daily dose far exceeds the vitamin requirement because the normal transporter protein-mediated absorption is absent, leaving only inefficient intestinal passive absorption. Injection side effects include skin rash, itching, chills, fever, hot flushes, nausea and dizziness. There are not enough studies on whether pills are as effective in improving or eliminating symptoms as parenteral treatment.
Explorations of artificial materials for manipulating electromagnetic waves began at the end of the 19th century. Some of the earliest structures that may be considered metamaterials were studied by Jagadish Chandra Bose, who in 1898 researched substances with chiral properties. Karl Ferdinand Lindman studied wave interaction with metallic helices as artificial chiral media in the early twentieth century. In the late 1940s, Winston E. Kock from AT&T Bell Laboratories developed materials that had similar characteristics to metamaterials. In the 1950s and 1960s, artificial dielectrics were studied for lightweight microwave antennas. Microwave radar absorbers were researched in the 1980s and 1990s as applications for artificial chiral media. Negative-index materials were first described theoretically by Victor Veselago in 1967. He proved that such materials could transmit light. He showed that the phase velocity could be made anti-parallel to the direction of Poynting vector. This is contrary to wave propagation in naturally occurring materials. In 1995, John M. Guerra fabricated a sub-wavelength transparent grating (later called a photonic metamaterial) having 50 nm lines and spaces, and then coupled it with a standard oil immersion microscope objective (the combination later called a super-lens ) to resolve a grating in a silicon wafer also having 50 nm lines and spaces. This super-resolved image was achieved with illumination having a wavelength of 650 nm in air.
The non-protein amino acid-accumulating clade, also known as the Canavanine-accumulating clade, is a clade of the flowering plant subfamily Faboideae (or Papilionoideae) that includes the majority of agriculturally-cultivated legumes. It is characterized by the accumulation of the non-proteinogenic amino acid canavanine in the seeds—a deterrent against herbivory. This phylogenetic trait was first recognized in the early 1980s. This clade is consistently resolved in molecular phylogenies. It contains many economically important genera, including Cicer, Glycine, Medicago, Phaseolus, Trifolium, Vicia, and Vigna.
, statistical functions introduced to match the assumed Gaussian distribution of asperities. Matthew Leighton et al. presented fits for crosshatched IC engine cylinder liner surfaces together with a process for determining the
Sources: en.wikipedia.org
=== Pharmacodynamics === Benorterone is an antiandrogen, or an antagonist of the androgen receptor (AR), the biological target of the androgen sex hormones testosterone and dihydrotestosterone. In one study, the affinity of benorterone for the AR was found to be about 5-fold greater than that of cyproterone acetate in rat prostate cytosol; the Ki values were 0.7 nM for benorterone and 3.7 nM for cyproterone acetate, which were 243% and 46% of those of testosterone (Ki = 1.7 nM), respectively. However, another study found that benorterone had only 11% of the affinity of dihydrotestosterone for the androgen receptor. Although an antiandrogen, benorterone actually is a very weak partial agonist of the AR and has been reported to possess weak androgenic activity. The same is true for cyproterone acetate and other steroidal antiandrogens. Unlike certain other steroidal antiandrogens such as cyproterone acetate, benorterone is not also a progestogen, instead being described as a selective and pure AR antagonist similarly to nonsteroidal antiandrogens such as flutamide and bicalutamide. However, although it is described as not being a progestogen, benorterone was found to produce "a highly variable decrease in plasma testosterone levels," indicating that it has weak antigonadotropic effects. The reasons for this are unclear, as other pure antiandrogens such as cyproterone (not cyproterone acetate) and flutamide do not do this and instead produce consistent increases in testosterone levels.
In 1992, whilst studying for his PhD, he also ran the London Marathon, in a time of 4 hours and 41 minutes, to raise money to buy a computer for a young boy with physical disabilities. Skinner's PhD involved developing genetic tests to detect congenital adrenal hyperplasia in children. He had work published in a number of scientific journals. In 1994 he had his work published in Human Molecular Genetics. In 1994, Skinner married Dr. Monica Schneider (also a molecular biologist), and in 1996 their son James was born. From 1994 to 1996 Skinner worked as a Post-Doctoral Research Fellow at Vanderbilt University Medical Center, in Nashville, Tennessee. The work he carried out there involved gene sequencing and protein purification of cytochrome P450 enzymes. His work was published in the Journal of Biological Chemistry. From 1996 to 1997 Skinner took care of his infant son, James, whilst his wife continued to work at Vanderbilt University Medical Center.
=== Childbirth === The vulvar region is at risk for trauma during childbirth. During childbirth, the vagina and vulva must stretch to accommodate the baby's head (approximately 9.5 cm (3.7 in)). This can result in tears known as perineal tears in the vaginal opening, and other structures within the perineum. An episiotomy (a pre-emptive surgical cutting of the perineum) is sometimes performed to facilitate delivery and limit tearing. A tear takes longer to heal than an incision. Tears and incisions may be repaired using sutures that may be layered. Among the methods of hair removal evaluated for pre-surgeries, pubic hair shaving known as prepping, was seen to increase the risk of surgical site infections. No advantages have been demonstrated in the routine shaving of pubic hair prior to childbirth.
== References == Allen, Ira (1969) [1798]. The natural and political history of the State of Vermont, one of the United States of America. Charles E. Tuttle Company. ISBN 0-8048-0419-2. Cooper, Grace Rogers (1973). Thirteen Star Flags (PDF). Smithsonian Institution Press. Archived (PDF) from the original on 2022-10-09. Tuttle, Mrs. George F. (1909). 300 Years In The Champlain Valley. Saranac, NY: Daughters of the American Revolution. Van de Water, Frederic Franklyn (1974). The Reluctant Republic: Vermont 1724–1791. The Countryman Press. ISBN 0-914378-02-3. Shalhope, Robert. (1996). Bennington and the Green Mountain Boys: The Emergence of Liberal Democracy in Vermont, 1760-1850. Johns Hopkins University Press
A basic chestnut or "red" horse has a solid copper-reddish coat, with a mane and tail that is close to the same shade as the body coat. Sorrel is a term used by American stock horse registries to describe red horses with manes and tails the same shade or lighter than the body coat color. In these registries, chestnut describes the darker shades of red-based coats.
Sources: en.wikipedia.org
== Therapies == A decade after the discovery of the RNAi mechanism in 1998, the pharmaceutical sector heavily invested in the research and development of siRNA therapy. There are several advantages that this therapy has over small molecules and antibodies. It can be administered quarterly or every six months. Another advantage is that, unlike small molecules and monoclonal antibodies that need to recognize a specific protein conformation, siRNA functions by Watson-Crick basepairing with mRNA. Therefore, any target molecule that needs to be treated with high affinity and specificity can be selected if the right nucleotide sequence is available. One of the biggest challenges researchers needed to overcome was the identification and establishment of a delivery system through which the therapies would enter the body. Another was that the immune system often mistakes RNAi therapies for remnants of infectious agents, which can trigger an immune response. Animal models did not accurately represent the degree of immune response seen in humans, and despite the promise of the treatment, investors divested from RNAi. However, there were a few companies that continued with the development of RNAi therapy for humans. Alnylam Pharmaceuticals, Sirna Therapeutics and Dicerna Pharmaceuticals are few of the companies still working on bringing RNAi therapies to market. It was learned that almost all siRNA therapies administered in the bloodstream accumulated in the liver. That is why most of the early drug targets were diseases that affected the liver.
== In fossils == In 2016, scientists reported the discovery of an osteosarcoma tumor in a 1.6–1.8 million-year-old fossil from the skeleton of the now-extinct hominin species Australopithecus sediba, making it the earliest-known case of human cancer.
According to the DSM, it "is the more specific DSM-5 diagnostic category in which erectile dysfunction persists for at least 6 months and causes distress in the individual." The ICD-10, to which the DSM refers regarding Erectile dysfunction, lists it under Failure of genital response (F52.2). The latest edition of the ICD – namely, the ICD-11 – lists the condition as Male erectile dysfunction (HA01.1).
=== Partition coefficient === Study of the solubility data shows that bronopol has a high affinity for polar rather than non-polar environments. In two-phase systems, bronopol partitions preferentially into the polar (usually aqueous) phase.
The system studied – the part of the patient that is the object of the examination (blood plasma, pituitary gland, skin, kidney, whole body) The component – the specific part or process that is of interest in the system studied (glucose, hormone secretion, bacteria, urine excretion) The kind-of-property - (amount-of-substance concentration, secretion rate, number, volume) An SI unit or WHO where relevant – (for measurable properties, i.e. differential or rational [not ordinal] quantities). These statements are ordered in a fixed syntax:
Sources: en.wikipedia.org
It mirrors the 44-residue form of human growth hormone-releasing hormone. A hexenoyl group on the N-terminal tyrosine distinguishes it from the unmodified hormone. The change is intended to improve resistance to enzymatic breakdown.
The N-terminal modification reduces cleavage by circulating peptidases, so the peptide persists longer than native GHRH. That persistence is the main rationale for the synthetic design. Comparative half-life values in humans are reported in regulatory review documents rather than in general reference literature.
Reductions in visceral adipose tissue have been measured in controlled studies of defined populations. Whether the effect generalizes to other groups and persists after treatment stops is less clear. Longer-term outcome data remain limited.
tesamorelin 属 GHRH 类似物，作用于垂体受体以促进内源生长激素释放；生长激素本身是直接补充的外源激素。两者在给药逻辑、作用位点和反馈调控路径上并不相同。